atorvastatin has been researched along with Acute Coronary Syndrome in 177 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 49 (27.68) | 29.6817 |
| 2010's | 111 (62.71) | 24.3611 |
| 2020's | 17 (9.60) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, KH; Choi, SH; Gwon, HC; Hahn, JY; Jang, YH; Jeong, DS; Kim, WS; Lee, YT; Song, YB | 1 |
| Abusoglu, G; Abusoglu, S; Erdem, K; Eryavuz Onmaz, D; Sivrikaya, A; Unlu, A; Yaglioglu, H | 1 |
| Banerjee, P; Damask, A; Fazio, S; Lin, N; Manvelian, G; Murphy, WA; Paulding, C; Pordy, R; Schwartz, GG; Shuldiner, AR; Steg, PG; Szarek, M | 1 |
| Hao, Y; Li, J; Wang, YC; Yang, YL | 1 |
| Bellandi, F; Biagini, F; Comeglio, M; Leoncini, M; Magnaghi, G; Maioli, M; Martini, O; Toso, A; Villani, S | 1 |
| Bai, D; Hong, D; Liang, X; Ma, Y; Wang, Y; Zhang, Y; Zhao, N | 1 |
| Mahmood, MM; Nawaz, MJ | 1 |
| Liu, W; Ma, W; Mu, J | 1 |
| Hu, WS; Lin, CL; Yu, TS | 1 |
| Banach, M; Bielecka-Dąbrowa, A; Desperak, P; Dudek, D; Dyrbuś, K; Gąsior, M; Gierlotka, M; Jankowski, P; Lewek, J; Niedziela, J; Osadnik, T; Witkowski, A | 1 |
| Amini, P; Cook, S; Crljenica, C; Deckarm, O; Gencer, B; Häner, J; Heg, D; Iglesias, JF; Koskinas, KC; Mach, F; Matter, CM; Mueller, C; Muller, O; Pedrazzini, G; Räber, L; Windecker, S | 1 |
| Cummings, JL; Ginsberg, HD; Johansson, JO; Kalantar-Zadeh, K; Kulikowski, E; Nicholls, SJ; Ray, KK; Schwartz, GG; Sweeney, M; Toth, PP; Wong, N | 1 |
| Alexander, JH; Berwanger, O; Damiani, LP; de Barros E Silva, PGM; Granger, CB; Lopes, RD; Santos, RHN | 1 |
| Fujimoto, K; Fujisue, K; Hokimoto, S; Ishihara, M; Izumiya, Y; Kaikita, K; Koide, S; Matsui, K; Matsumura, T; Matsuyama, K; Miyazaki, T; Morikami, Y; Nagamatsu, S; Nakamura, S; Nakao, K; Ogawa, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Chen, JY; Chen, PY; Duan, CY; Fan, HL; Guo, W; Guo, ZQ; He, PC; He, WF; Jiang, L; Liu, YH; Tan, N; Tao, S; Wei, XB; Zeng, LH | 1 |
| Bulas, J; Gašpar, U; Klabník, A; Murín, J; Wawruch, M | 1 |
| Al-Shekh, I; Al-Yafei, S; AlAhmad, Y; Aljundi, AH; Alzaeem, H; Arabi, AR; Awaisu, A; Habra, M; Khir, F; Mahfouz, A; Rahhal, A | 1 |
| Abdelghani, MS; Al-Awad, M; Al-Khalaila, O; Alahmad, Y; Aljundi, AH; Alyafei, S; Arabi, AR; Ashour, AA; Awaisu, A; Chbib, S; Khir, F; Mahfouz, A; Orabi, B; Osman, O; Rahhal, A | 1 |
| Borovac, JA; Bozic, J; D'Amario, D; Glavas, D; Kumric, M; Leth-Olsen, M; Schwarz, K | 1 |
| Angelini, G; Biasucci, LM; Campioni, M; Crea, F; Flego, D; Giglio, AF; Giubilato, S; Iaconelli, A; Liuzzo, G; Lucci, C; Pazzano, V; Pedicino, D; Ruggio, A; Severino, A; Trotta, F; Zara, C | 1 |
| Japaridze, L; Sadunishvili, M | 1 |
| Kochubiei, O; Ovrakh, T; Serik, S | 1 |
| Lapa, T; Montenegro Sá, F; Simões, I; Vieira Marques, F | 1 |
| Geng, Q; Guo, L; Liu, Y; Liu, Z; Ma, H; Wang, P; Xie, H; Zhan, H; Zhang, G | 1 |
| Amano, T; Fujiwara, H; Hibi, K; Ishii, H; Kawasaki, M; Kimura, K; Koshida, R; Kozuma, K; Miyamoto, T; Morino, Y; Morita, S; Murohara, T; Otsuji, Y; Ozaki, Y; Sata, M; Sato, K; Sonoda, S | 1 |
| Fusazaki, T; Ishikawa, Y; Itoh, T; Morino, Y; Nakajima, S; Nakamura, M; Satoh, M; Sugawara, S | 1 |
| Cannon, CP; Guo, J; Khan, N; Steen, DL; Umez-Eronini, AA | 1 |
| Fu, N; Liang, M; Yang, S | 1 |
| Fang, M; Li, X; Qian, Q; Su, J; Zhao, Z; Zhu, L | 1 |
| Alexander, JH; Armaganijan, LV; Baldissera, F; Barbosa, LM; Beraldo de Andrade, P; Berwanger, O; Bienert, IRC; Borges de Oliveira, JA; Bosso, CE; Cavalcanti, AB; Dall Orto, FTC; Damiani, LP; de Barros E Silva, PGM; Egydio, FM; Giraldez, RRCV; Granger, CB; Guimarães, HP; Jesuíno, IA; Kalil, RAK; Laranjeira, LN; Lopes, RD; Mangione, JA; Mattos, LA; Nascimento, BR; Pereira, SB; Polanczyk, CA; Rech, RL; Santos, LM; Santos, RHN; Santucci, EV; Sousa, ACS; Sousa, AGMR; Sousa, JEMR; Sposito, AC | 1 |
| Alexander, JH; Armaganijan, LV; Baldissera, F; Berwanger, O; Borges de Oliveira, JA; Bosso, CE; Cavalcanti, AB; Dall Orto, FTC; Damiani, LP; de Andrade Jesuíno, I; de Andrade, PB; de Barros E Silva, PGM; de Castro Bienert, IR; de Moura Santos, L; Giraldez, RR; Granger, CB; Guimarães, HP; Kalil, R; Laranjeira, LN; Lopes, RD; Mangione, J; Mattos, LA; Nascimento, BR; Pereira, SB; Polanczyk, CA; Rech, RL; Santucci, EV; Sousa, A; Sousa, ACS; Sousa, JE; Sposito, AC | 1 |
| Ryabov, VV; Sultanov, VS; Trusov, VB; Tsoy, EI; Vyshlov, EV | 1 |
| Alexander, JH; Barbosa, LM; Beraldo de Andrade, P; Berwanger, O; Dall Orto, FTC; Damiani, LP; de Andrade Jesuíno, I; de Barros E Silva, PGM; de Castro Bienert, IR; Granger, CB; Laranjeira, LN; Lopes, RD; Nakagawa Santos, RH; Santucci, EV | 1 |
| Aoi, S; Golfeyz, S; Harrington, M; Kobayashi, T | 1 |
| Ma, Y; Xiang, C; Zhang, B | 1 |
| Altunkeser, BB; Ates, MS; Aygul, N; Demir, K; Ozturk, B; Tezcan, H; Tuncez, A; Yalcin, MU; Yilmaz, C | 1 |
| Davies, A; Lüscher, TF | 1 |
| Althouse, AD; Turgeon, RD | 1 |
| Huang, Z; Li, Q; Li, X; Ye, W; Zhang, Q | 1 |
| Bu, L; Cao, H; Guo, R; Lu, L; Luo, L; Ma, M; Shi, L; Yang, B | 1 |
| Bare, LA; Devlin, JJ; Iakoubova, OA; Leahy, KJ; O'Sullivan, AK; Parthan, A; Weinstein, MC | 1 |
| Buszman, P; Cybulski, W; Dworowy, S; Jadczyk, T; Kawecki, D; Król, M; Milewski, K; Ochała, A; Pawłowski, T; Pyrlik, A; Rudnik, A; Smolka, G; Tendera, M; Wojakowski, W; Wyderka, R | 1 |
| Gong, HR; Huang, WY; Huang, XS; Li, XP; Zhao, SP | 1 |
| Calabria, P; Limbruno, U; Micheli, A; Picchi, A | 1 |
| Ge, J; Jang, Y; Ji, C; Kim, YJ; Lam, W; Zhu, J | 1 |
| Bash, D; Brennan, DM; Cavender, MA; Jukema, JW; Kastelein, JJ; Koenig, W; Lincoff, AM; Menon, V; Nambi, V; Nicholls, SJ; Nissen, SE; Rosenson, RS; Schwartz, GG; Wright, RS | 1 |
| Barkate, H; Dalal, J; Dani, S; Hiremath, MS; Jindal, C; Kahali, D; Kaul, U; Ramchandran, P; Rane, R; Varma, J | 1 |
| Gong, HR; Huang, WY; Li, XP; Zhao, SP | 1 |
| Huo, Y; Peng, DQ; Yu, BL; Zhao, SP | 2 |
| Bellandi, F; Colonna, G; Di Sciascio, G; Grieco, D; Leoncini, M; Maioli, M; Patti, G; Toso, A | 1 |
| Cannon, CP; de Lemos, J; Guo, J; Lewis, EF; Mega, JL; O'Donoghue, ML; Rouleau, JL; Sabatine, MS; Sarma, A | 1 |
| Andersen, M; Fazylov, R; Goriacko, P; Plakogiannis, R | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K | 1 |
| Berdan, LG; Bessac, L; Bhatt, DL; Bittner, V; Diaz, R; Goodman, SG; Hanotin, C; Harrington, RA; Jukema, JW; Mahaffey, KW; Moryusef, A; Pordy, R; Roe, MT; Rorick, T; Sasiela, WJ; Schwartz, GG; Shirodaria, C; Steg, PG; Szarek, M; Tamby, JF; Tricoci, P; White, H; Zeiher, A | 1 |
| Einecke, D | 1 |
| Ding, Y; Feng, GK; Jiang, XJ; Li, XY; Wang, CQ; Wang, ZX | 1 |
| Li, L; Li, Y; Shen, J; Shen, Y; Su, F; Zhang, D; Zhang, M | 1 |
| Bruthans, J; Mayer, O | 1 |
| Cannon, CP; Khera, AV; Murphy, SA; Qamar, A; Rader, DJ; Sabatine, MS | 1 |
| Fayez, G; Nassar, A; Shehata, M | 1 |
| Cai, JX; Deng, SB; Du, J; Du, JL; Liu, YJ; Qu, GS; She, Q; Wang, DQ; Zhang, JR | 1 |
| De Caterina, R; Di Sciascio, G; Grieco, D; Madonna, R; Patti, G; Ricottini, E; Stampachiacchiere, B; Tonini, G; Zoccoli, A | 1 |
| Chen, LZ; Huang, XS; Li, R; Zhao, SP | 1 |
| Austin, PC; Chong, A; Jackevicius, CA; Ko, DT; Koh, M; Krumholz, HM; Ross, JS; Stukel, TA; Tu, JV | 1 |
| Japaridze, L; Megreladze, I; Sadunishvili, M | 1 |
| Chu, Y; Hao, H; Hu, S; Joerg, H; Li, B; Liu, Z; Sang, C; Xia, J; Xu, D; Xu, J | 1 |
| Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Bonaca, MP; Braunwald, E; Cannon, CP; Conrad, MJ; Jarolim, P; Morrow, DA; Murphy, SA; O'Malley, RG; Sabatine, MS; Scirica, BM; White, HD | 1 |
| Hao, H; Li, J; Liu, Z; Wang, Y; Xu, D; Xu, J; Xu, Y; Yin, C | 1 |
| Daida, H; Dohi, T | 2 |
| Chen, Q; Liang, L; Shang, X; Yuan, M; Zhong, X | 1 |
| Al Danaf, J; Duffy, D; Panakos, A; Ragupathi, L; Valentino, M; Whellan, D | 1 |
| Berringer, R; Wonnacott, D | 1 |
| Braunwald, E; Cannon, CP; Daga, S; Dalby, AJ; Eisen, A; Goodrich, EL; Im, K; Lukas, MA; O'Donoghue, ML; Spinar, J; Steen, DL; Zhou, J | 1 |
| Chu, Y; Hao, H; Li, J; Liu, Z; Xu, D; Yin, C | 1 |
| Blanco-Colio, LM; Egido, J; Gómez-Hernández, A; Jiménez-Nacher, JJ; López-Bescos, L; Martín-Ventura, JL; Ortego, M; Sánchez-Galán, E; Tarín-Vicente, N; Tuñón, J | 1 |
| Kasyanova, O; Shpektor, A; Vasilieva, E | 1 |
| Nambi, V; Polsani, VR; Virani, SS | 1 |
| Badyal, DK; Chopra, S; Gupta, A; Jaison, TM; Khosla, PP; Uppal, B | 1 |
| Acharjee, S; Welty, FK | 1 |
| Czechowska, M; Goracy, J; Kaliszczak, R; Kaźmierczak, J; Kornacewicz-Jach, Z; Lewandowski, M; Millo, B; Naruszewicz, M; Płońska, E; Zielonka, J | 1 |
| Beitelshees, AL; Chegini, N; Cresci, S; Hou, W; Province, MA; Spertus, JA; Welder, GJ; Wu, J; Zineh, I | 1 |
| Boccara, F; Hatem, S | 1 |
| Alonso, J; Crean, P; Danchin, N; Farah, M; Farnier, M; Lablanche, JM; Leone, A; Licour, M; Morais, J; Santini, M; Tardif, JC; Tedgui, A; Vicaut, E | 1 |
| Barrios, V; Echarri, R; Escobar, C | 1 |
| Abad, L; de Luis, D; Duenas-Laita, A; Gonzalez Sagredo, M; Pérez-Castrillón, JL; Sanz-Cantalapiedra, A; Vega, G | 1 |
| Abad, L; De Luis, D; Duenas-Laita, A; Pérez-Castrillón, JL; Sagredo, MG; Sanz-Cantalapiedra, A; Vega, G | 1 |
| Shen, J; Zhang, Q; Zhang, RY | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Morrow, DA; Ray, KK; Ridker, PM | 1 |
| Barderas, MG; Dardé, VM; De la Cuesta, F; Egido, J; Jiménez-Nácher, JJ; López-Bescós, L; Tarín, N; Tuñón, J; Vivanco, F | 1 |
| Cannon, CP; Gibson, CM; McCabe, CH; Murphy, SA; Tung, P; Wiviott, SD | 1 |
| Ahn, CM; Hong, SJ; Kim, KA; Kim, YH; Lim, DS; Park, JS; Park, JY; Park, SM; Shim, WJ | 1 |
| Bao, W; Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Schwartz, GG | 1 |
| Karadağ, B; Ongen, Z; Yilmaz, Y | 1 |
| Fraley, AE; Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Schwartz, GG; Szarek, M; Tsimikas, S; Witztum, JL | 1 |
| Cho, L; Jacob, M | 1 |
| Daida, H; Hiro, T; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Saito, S; Yamagishi, M; Yamaguchi, T | 2 |
| Brown, A; Cannon, CP; Mega, JL; Morrow, DA; Sabatine, MS | 1 |
| Boari, B; Manfredini, F; Manfredini, R; Salmi, R | 1 |
| Bertrand, OF; Cossette, M; Grégoire, J; Guertin, MC; Ibrahim, R; L'allier, PL; Larose, E; Rodés-Cabau, J; Tardif, JC | 1 |
| Cannon, CP; Gibson, CM; Hochberg, CP; Pride, YB; Sabatine, MS; Sloan, S | 1 |
| Daida, H; Dohi, T; Kojima, T; Kurata, T; Miyauchi, K; Okazaki, S; Tamura, H; Yanagisawa, N; Yokoyama, K; Yokoyama, T | 2 |
| Braunwald, E; Cannon, CP; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Kaneda, H; Ma, J; Morita, T | 1 |
| Liu, L; Zhao, SP; Zheng, XY | 1 |
| Gratsianskiĭ, NA; Kuznetsova, MA; Masenko, VP; Vaulin, NA | 1 |
| Acharjee, S; Cannon, CP; McCabe, C; Murphy, SA; Qin, J | 1 |
| King, S; Momary, K; Superko, HR | 1 |
| Lavie, CJ; Milani, RV | 1 |
| Ge, J; Jang, YS; Kim, YJ; Lam, W; Marschner, IC; Zhu, J | 1 |
| Cairns, R; Cannon, CP; Michael Gibson, C; Nazer, B; Ray, KK | 1 |
| Alonso, J; Demil, N; Eha, J; Lablanche, JM; Leone, A; Licour, M; Merkely, B; Morais, J; Santini, M; Tardif, JC | 1 |
| Di Sciascio, G; Melfi, R; Nusca, A; Patti, G | 2 |
| Bonassin, F; Schneemann, M; Wyss, C | 1 |
| Alfano, G; Chello, M; Covino, E; Di Sciascio, G; Gatto, L; Miglionico, M; Patti, G | 1 |
| Kruger, A; Ostadal, P; Vondrakova, D | 1 |
| Colivicchi, F; Santini, M; Tubaro, M | 1 |
| Arai, H; Daida, H; Hiro, T; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Saito, S; Yamagishi, M; Yamaguchi, T | 1 |
| Daida, H; Hiro, T; Ichimiya, S; Ishii, H; Kanashiro, M; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Murohara, T; Nakagawa, Y; Ohashi, T; Ozaki, Y; Shibata, R; Yamagishi, M | 1 |
| He, XZ; Wan, XH; Wang, HY; Xue, JF; Zhong, QH; Zhou, SH | 2 |
| Cannon, CP; Khera, AV; Qin, J; Rader, DJ; Wolfe, ML | 1 |
| Alessi, MC; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Moro, PJ; Poyet, R; Quilici, J | 1 |
| Elliott, M; Goulder, M; Hislop, C; Rosenson, RS; Stasiv, Y; Waters, D | 1 |
| Bangalore, S; Cannon, CP; Murphy, SA; Qin, J; Sloan, S | 1 |
| Gao, Y; Pang, X; Qi, G; Sun, Y; Zhang, H; Zhang, Z; Zhao, W | 1 |
| Mareev, VIu | 1 |
| Chen, WQ; Ge, ZM; Geng, J; Ji, XP; Ren, SD; Wu, TT; Yu, XL; Zhang, HJ; Zhong, L | 1 |
| Rosenson, RS | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Nazer, B; Ray, KK; Scirica, B; Sloan, S | 1 |
| Caretta, G; Dei Cas, L; Della Pina, P; Gorga, E; Madureri, A; Raddino, R | 1 |
| Armani, A; Cannon, CP; McCabe, CH; Murphy, SA; Truong, QA | 1 |
| Colonna, G; D'Ambrosio, A; Di Sciascio, G; Montinaro, A; Nusca, A; Pasceri, V; Patti, G; Ricottini, E | 1 |
| Cannon, CP; De Lemos, JA; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Wilson, SR; Wiviott, SD; Zhou, S | 1 |
| Daida, H; Hibi, K; Hiro, T; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Saito, S; Yamagishi, M; Yamaguchi, T | 1 |
| Fraser, H; Goulder, MA; Hislop, C; Rosenson, RS | 1 |
| Bash, D; Cavender, MA; Hislop, C; Kastelein, JJ; Nicholls, SJ; Rosenson, RS; Schwartz, G; Waters, DD | 1 |
| Braunwald, E; Cannon, CP; Grandin, EW; Jarolim, P; Morrow, DA; Murphy, SA; Ritterova, L | 1 |
| Bao, W; Benessiano, J; Mallat, Z; Olsson, AG; Ryu, SK; Schwartz, GG; Tedgui, A; Tsimikas, S | 1 |
| Cai, WQ; Chai, DJ; Chen, GL; Chen, XP; Huang, QY; Su, JZ; Wang, FB; Xue, Y; Zhang, DS | 1 |
| Loscalzo, J; Miller, E; Monyak, J; Pitt, B; Raichlen, J | 1 |
| Bonaca, MP; Bui, AH; Cannon, CP; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS | 1 |
| Nishigaki, K | 1 |
| Daida, H; Hasegawa, Y; Hirayama, A; Hiro, T; Kadota, K; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Uchiyama, S; Yamagishi, M | 1 |
| Miyauchi, K | 1 |
| Hasebe, N; Ota, H; Takeuchi, T | 1 |
| Banaszewska, A; Dudziak, J; Piechota, M; Plewa, R; Slomczynski, M | 1 |
| Chang, K; Gwon, HC; Jeon, DS; Kim, HS; Kim, MJ; Kim, SJ; Tahk, SJ | 1 |
| Amano, T; Asai, K; Daida, H; Hiro, T; Kimura, T; Kosaka, T; Kuhara, Y; Kurita, A; Kuroda, Y; Maeda, K; Matsuzaki, M; Miyauchi, K; Mizuno, T; Morimoto, T; Nakagawa, Y; Ozaki, Y; Takashima, H; Yamagishi, M | 1 |
| Fujii, K; Masuyama, T | 1 |
| Daida, H; Hiro, T; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ogita, M; Ozaki, Y; Yamagishi, M | 1 |
| Cannon, CP; Gibson, CM; Murphy, SA; Nazer, B; Ray, KK | 1 |
| Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Vaulin, NA | 1 |
| Chen, HZ; Chen, KQ; Dong, SH; Huang, ZX; Jiang, X; Li, YF; Liang, XJ; Liu, HD; Luo, LJ; Wen, JM | 1 |
| Goudevenos, JA; Lourida, ES; Papathanasiou, AI; Tselepis, AD; Tsironis, LD | 1 |
| Erdogan, O; Ordulu, E | 1 |
| deGoma, EM; Fonarow, GC; Rockson, SG | 1 |
| Michałek, A | 1 |
| Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Schwartz, GG; Szarek, M; Waters, DD | 1 |
| Cannon, CP; Kumar, A | 1 |
| Hu, Y; Hu, Z; Li, D; Yang, K | 1 |
| Han, YL; Kang, J; Li, CY; Li, Y; Yan, CH | 1 |
| Braunwald, E; Buros, J; Cannon, CP; Croce, K; Gao, H; Healy, AM; Libby, P; McCabe, CH; Morrow, DA; Pradhan, AD; Sabatine, MS; Sakuma, M; Simon, DI; Wang, Y | 1 |
| Conover, CA; Harrington, SC; Henry, TD; MacDonald, H; Miedema, MD; Oberg, D; Schwartz, RS; Wilson, D | 1 |
| Blazing, M; Cannon, CP; Gersh, B; McLean, DS; Ravid, S; Shui, A | 1 |
| Braunwald, E; Cannon, CP; Miller, M; Murphy, SA; Qin, J; Ray, KK | 1 |
| Bybee, KA; Lee, JH; O'Keefe, JH | 1 |
| Miller, M | 1 |
| Loscalzo, J; Pitt, B; Raichlen, JS; Ycas, J | 1 |
| Farmer, JA; Jones, PH | 1 |
| Liew, TV; Ray, KK | 1 |
| Cannon, CP; Giugliano, GR; Lotfi, A; Murphy, SA; Schweiger, MJ | 1 |
19 review(s) available for atorvastatin and Acute Coronary Syndrome
| Article | Year |
|---|---|
A Comparative Study of High-intensity Rosuvastatin Versus Atorvastatin Therapy Post-acute Coronary Syndrome Using Real-world Data.
Topics: Acute Coronary Syndrome; Aftercare; Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Discharge; Retrospective Studies; Rosuvastatin Calcium; Treatment Outcome | 2022 |
Efficacy of high-dose atorvastatin or rosuvastatin loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials with GRADE qualification of available evidence.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic; Rosuvastatin Calcium | 2022 |
Efficacy Evaluation of High-Dose Atorvastatin Pretreatment in Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Adult; Aged; Atorvastatin; C-Reactive Protein; Creatine Kinase, MB Form; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Time Factors; Treatment Outcome | 2018 |
Effect of loading dose of atorvastatin therapy prior to percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of six randomized controlled trials.
Topics: Acute Coronary Syndrome; Atorvastatin; Dose-Response Relationship, Drug; Humans; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic; Structure-Activity Relationship | 2019 |
What Is the Appropriate Duration of High-Dose Atorvastatin Therapy Post-Acute Coronary Syndrome?
Topics: Acute Coronary Syndrome; Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Time Factors | 2015 |
Spontaneous coronary artery dissection: Case report and review of the literature.
Topics: Acute Coronary Syndrome; Adrenergic beta-1 Receptor Antagonists; Adult; Aspirin; Atorvastatin; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Echocardiography; Electrocardiography; Female; Humans; Metoprolol; Platelet Aggregation Inhibitors; Ticlopidine; Vascular Diseases | 2016 |
Atorvastatin and cardiovascular risk in the elderly--patient considerations.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic | 2008 |
Relative safety profiles of high dose statin regimens.
Topics: Acute Coronary Syndrome; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Muscle, Skeletal; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin | 2008 |
[Atorvastatin in secondary prevention].
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pyrroles; Secondary Prevention; Stroke | 2009 |
Lipid reduction in acute coronary syndrome: how much, when, and how?
Topics: Acute Coronary Syndrome; Atorvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Meta-Analysis as Topic; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin | 2009 |
Statin loading for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cytokines; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Oxidative Stress; Preoperative Care; Pyrroles; Time Factors | 2010 |
[Indications for statin therapy in patients with acute coronary syndrome of ischemic origin].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol; Electrocardiography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention | 2010 |
[Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study].
Topics: Acute Coronary Syndrome; Atorvastatin; Endosonography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrroles | 2011 |
[Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-aCS) study].
Topics: Acute Coronary Syndrome; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2011 |
Reinforcing a continuum of care: in-hospital initiation of long-term secondary prevention following acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiology; Clinical Trials as Topic; Continuity of Patient Care; Disease Management; Guideline Adherence; Heptanoic Acids; Hospital Mortality; Hospitalization; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Preventive Medicine; Pyrroles | 2007 |
Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ultrasonography, Interventional | 2007 |
Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Heptanoic Acids; Humans; Kidney Failure, Chronic; Pyrroles; Risk Factors; Stroke | 2008 |
Adjunctive interventions in myocardial infarction: the role of statin therapy.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Circulation; Coronary Occlusion; Dyslipidemias; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Plasminogen Activator Inhibitor 1; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2008 |
Intensive statin therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Atorvastatin; Blood Platelets; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin | 2008 |
111 trial(s) available for atorvastatin and Acute Coronary Syndrome
| Article | Year |
|---|---|
Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial.
Topics: Acute Coronary Syndrome; Antigens, CD; Atorvastatin; Cholesterol, LDL; Creatine Kinase; Genome-Wide Association Study; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Proteins; Muscles; PCSK9 Inhibitors; Pharmacogenomic Testing; Receptors, Immunologic; Rosuvastatin Calcium | 2022 |
Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Percutaneous Coronary Intervention; Prognosis; Proprotein Convertase 9; Prospective Studies; Treatment Outcome | 2022 |
Rationale and design of COLchicine On-admission to Reduce inflammation in Acute Coronary Syndrome (COLOR-ACS) study.
Topics: Acute Coronary Syndrome; Atorvastatin; C-Reactive Protein; Colchicine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Treatment Outcome | 2023 |
Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).
Topics: Acute Coronary Syndrome; Aged; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Feasibility Studies; Female; Hospitalization; Humans; Male; Middle Aged; Prospective Studies | 2019 |
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proteins; Quinazolinones; Renal Insufficiency, Chronic; Renin-Angiotensin System; Rosuvastatin Calcium; Stroke; Treatment Outcome | 2019 |
Effects of Statin Plus Ezetimibe on Coronary Plaques in Acute Coronary Syndrome Patients with Diabetes Mellitus: Sub-Analysis of PRECISE-IVUS Trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Diabetes Mellitus, Type 2; Drug Monitoring; Ezetimibe; Female; Humans; Male; Plaque, Atherosclerotic; Treatment Outcome; Ultrasonography, Interventional | 2021 |
The short-term effect of atorvastatin plus ezetimibe therapy versus atorvastatin monotherapy on clinical outcome in acute coronary syndrome patients by gender.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2017 |
[IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME].
Topics: Acute Coronary Syndrome; Aspirin; Atorvastatin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Type 2; Drug Interactions; Drug Substitution; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Rosuvastatin Calcium; Ticlopidine | 2017 |
Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, LDL; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Quinolines; Ultrasonography, Interventional | 2018 |
Impact of Water- and Lipid-Soluble Statins on Nonculprit Lesions in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Coronary Vessels; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Rosuvastatin Calcium; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2018 |
The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Atorvastatin; Biomarkers; Colorimetry; Dose-Response Relationship, Drug; Fasting; Female; Follow-Up Studies; Hospitalization; Humans; Immunoturbidimetry; Inflammation; Lipids; Lipoproteins; Male; Middle Aged; Pravastatin; Prognosis; Retrospective Studies | 2018 |
High Loading Dose of Atorvastatin for the Prevention of Serum Creatinine and Cystatin C-Based Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Aged; Atorvastatin; Biomarkers; Contrast Media; Creatinine; Cystatin C; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Treatment Outcome | 2018 |
High-Sensitivity C-Reactive Protein Combined with Low-Density Lipoprotein Cholesterol as the Targets of Statin Therapy in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies | 2018 |
Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Preoperative Care; ST Elevation Myocardial Infarction | 2018 |
Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Brazil; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Revascularization; Percutaneous Coronary Intervention; Postoperative Care; Preoperative Care; Prognosis; Proportional Hazards Models; Risk Assessment; Survival Rate; Treatment Outcome | 2018 |
Hypolipidemic and Hepatoprotective Effects of a Polyprenol-Containing Drug in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; gamma-Glutamyltransferase; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Plant Extracts; Survival Analysis; Triglycerides | 2018 |
Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Perioperative Care; Treatment Outcome | 2018 |
Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Proprotein Convertase 9; Rosuvastatin Calcium; Time Factors; Treatment Outcome; Triglycerides; Turkey | 2019 |
Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Atorvastatin; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; Genetic Testing; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Markov Chains; Middle Aged; Molecular Targeted Therapy; Pravastatin; Pyrroles; Quality-Adjusted Life Years | 2013 |
Circulating endothelial progenitor cells are inversely correlated with in-stent restenosis in patients with non-ST-segment elevation acute coronary syndromes treated with EPC-capture stents (JACK-EPC trial).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Coated Materials, Biocompatible; Coronary Restenosis; Drug-Eluting Stents; Endothelial Cells; Female; Follow-Up Studies; Heart Conduction System; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Radiography; Risk Factors; Stem Cells; Stents; Treatment Outcome | 2013 |
The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Apolipoprotein A-V; Apolipoproteins A; Atorvastatin; Bezafibrate; Cholesterol, HDL; Drug Synergism; Drug Therapy, Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2013 |
Preloading with atorvastatin before percutaneous coronary intervention in statin-naïve Asian patients with non-ST elevation acute coronary syndromes: A randomized study.
Topics: Acute Coronary Syndrome; Aged; Asian People; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Postoperative Care; Postoperative Complications; Preoperative Care; Pyrroles; Time Factors; Ultrasonography | 2014 |
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
Topics: Acetates; Acute Coronary Syndrome; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Heptanoic Acids; Humans; Indoles; Keto Acids; Male; Middle Aged; Myocardial Infarction; Phospholipases A; Phospholipases A2, Secretory; Pyrroles; Risk; Stroke; Survival Analysis; Treatment Outcome | 2014 |
Post-marketing study of clinical experience of atorvastatin 80 mg vs 40 mg in Indian patients with acute coronary syndrome- a randomized, multi-centre study (CURE-ACS).
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; India; Male; Middle Aged; Pyrroles; Secondary Prevention; Treatment Outcome | 2013 |
[The lipid-regulating effect and safety of combined statin and bezafibrate therapy in acute coronary syndrome patients complicating with dyslipidemia].
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Treatment Outcome | 2013 |
The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Agents; China; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2014 |
The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Atorvastatin; Creatinine; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Pravastatin; Pyrroles | 2014 |
Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Incidence; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography | 2014 |
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Topics: Acute Coronary Syndrome; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Stroke; Sulfonamides; Treatment Outcome | 2014 |
[IMPROVE-IT Study proves effectiveness of ezetimib. The Higgs particle of lipidologists].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Simvastatin | 2014 |
Changes of naturally occurring CD4(+)CD25(+) FOXP3(+) regulatory T cells in patients with acute coronary syndrome and the beneficial effects of atorvastatin treatment.
Topics: Acute Coronary Syndrome; Adult; Aged; Atorvastatin; CD4 Antigens; Cytokines; Female; Forkhead Transcription Factors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-2 Receptor alpha Subunit; Male; Middle Aged; Pyrroles; RNA, Messenger; T-Lymphocytes, Regulatory | 2015 |
Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; China; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2015 |
[In what extend we can reach the current LDL-cholesterol treatment goals in secondary prevention].
Topics: Acute Coronary Syndrome; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Goals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Retrospective Studies; Secondary Prevention; Treatment Outcome | 2015 |
On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study).
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Leptin; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pravastatin; Pyrroles; Recurrence; Resistin; Retrospective Studies; Risk Factors; Survival Rate; Thrombolytic Therapy; United States | 2015 |
Intensive Statin Therapy in NSTE-ACS Patients Undergoing PCI: Clinical and Biochemical Effects.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Down-Regulation; Drug Administration Schedule; Egypt; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Stroke Volume; Systole; Time Factors; Treatment Outcome; Ventricular Function, Left | 2015 |
Efficacy of Clopidogrel and Clinical Outcome When Clopidogrel Is Coadministered With Atorvastatin and Lansoprazole: A Prospective, Randomized, Controlled Trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Atorvastatin; Clopidogrel; Drug Interactions; Drug-Eluting Stents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lansoprazole; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Polypharmacy; Prospective Studies; Proton Pump Inhibitors; Ticlopidine; Treatment Outcome | 2015 |
Effect of High-Dose Atorvastatin Reload on the Release of Endothelial Progenitor Cells in Patients on Long-Term Statin Treatment Who Underwent Percutaneous Coronary Intervention (from the ARMYDA-EPC Study).
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cell Count; Dose-Response Relationship, Drug; Electrocardiography; Endothelial Progenitor Cells; Female; Flow Cytometry; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Percutaneous Coronary Intervention; Prospective Studies; Time Factors | 2016 |
COMBINATION THERAPY EFFECTIVENESS OF EZETIMIBE AND ATORVASTATIN IN PATIENTS WITH ACUTE CORONARY SYNDROME.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies | 2016 |
Efficacy of High-Intensity Atorvastatin for Asian Patients Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Atorvastatin; China; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lipids; Liver Function Tests; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Treatment Outcome; Troponin I | 2016 |
Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Treatment Outcome; Ultrasonography, Interventional | 2016 |
Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease.
Topics: Acute Coronary Syndrome; Atorvastatin; Biomarkers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Troponin I | 2016 |
Efficacy of high intensity atorvastatin versus moderate intensity atorvastatin for acute coronary syndrome patients with diabetes mellitus.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Long Term Adverse Effects; Male; Middle Aged; Percutaneous Coronary Intervention; Prognosis; Proportional Hazards Models; Treatment Outcome | 2016 |
Effect of atorvastatin on serum omentin-1 in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Atorvastatin; China; Coronary Artery Disease; Cytokines; Dose-Response Relationship, Drug; Female; GPI-Linked Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lectins; Male; Middle Aged; Time Factors; Treatment Outcome; Up-Regulation | 2017 |
Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Age Factors; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prognosis | 2017 |
Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Atorvastatin; Dinoprostone; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukotriene B4; Male; Matrix Metalloproteinase 9; Middle Aged; NF-kappa B; Pyrroles; Treatment Outcome | 2008 |
The antiplatelet effect of atorvastatin in patients with acute coronary syndrome depends on the hs-CRP level.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atorvastatin; C-Reactive Protein; Clopidogrel; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2008 |
The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Coronary Angiography; Coronary Restenosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Inflammation Mediators; Interleukin-6; Male; Middle Aged; Probability; Pyrroles; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome; Tumor Necrosis Factor-alpha | 2008 |
Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Double-Blind Method; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
[Impact of statins on clopidogrel platelet inhibition in patients with acute coronary syndrome or stable angina].
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angina Pectoris; Atorvastatin; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine | 2008 |
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Chi-Square Distribution; Dose-Response Relationship, Drug; Electrophoresis, Gel, Two-Dimensional; Female; Gene Expression; Gene Expression Profiling; Heat-Shock Proteins; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Monocytes; Pyrroles; Statistics, Nonparametric; Tandem Mass Spectrometry; Thrombosis | 2009 |
Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE
Topics: Acute Coronary Syndrome; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Seasons | 2009 |
Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Heptanoic Acids; Humans; Korea; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Single-Blind Method; Sirolimus; Ticlopidine; Time Factors | 2009 |
Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Female; Fibrin Fibrinogen Degradation Products; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Recurrence; Risk; Tissue Plasminogen Activator | 2009 |
Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardia
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Autoantibodies; Biomarkers; Cholesterol, LDL; Cohort Studies; Female; Heptanoic Acids; Humans; Immunoglobulin G; Immunoglobulin M; Inflammation; Lipoprotein(a); Male; Middle Aged; Oxidation-Reduction; Phospholipids; Pyrroles; Reactive Oxygen Species; Risk Factors; Thromboembolism | 2009 |
Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2009 |
Identification of genetic variants associated with response to statin therapy.
Topics: Acute Coronary Syndrome; Apolipoproteins E; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Cholesterol, LDL; Haplotypes; Heptanoic Acids; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Phenotype; Polymorphism, Genetic; Practice Guidelines as Topic; Pravastatin; Pyrroles; Treatment Outcome | 2009 |
Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Ultrasonography, Interventional | 2009 |
Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; China; Cholesterol, LDL; Dose-Response Relationship, Drug; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Prospective Studies; Pyrroles; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2009 |
Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis I
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Pyrroles | 2009 |
Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Disease-Free Survival; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome | 2010 |
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection T
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Regression Analysis; Secondary Prevention; Stroke | 2009 |
[Effects of atorvastatin, alone and in combination with probucol on endothelial function in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Middle Aged; Probucol; Pyrroles | 2009 |
[Non-ST-elevation acute coronary syndrome. Comparison of effects of atorvastatin and rosuvastatin on blood levels of lipids and markers of inflammation].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Data Interpretation, Statistical; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Lipids; Lipoproteins; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Statistics, Nonparametric; Sulfonamides; Tumor Necrosis Factor-alpha | 2010 |
Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial).
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol; Cohort Studies; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2010 |
Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers; China; Drug Tolerance; Electrocardiography; Heptanoic Acids; Humans; Korea; Premedication; Prospective Studies; Pyrroles; Treatment Outcome | 2010 |
Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Atorvastatin; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Observation; Pravastatin; Pyrroles; Treatment Outcome | 2010 |
Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2010 |
Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acut
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Coronary Artery Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2010 |
Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplas
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antigens, CD; Atorvastatin; Cadherins; Cell Adhesion Molecules; Chi-Square Distribution; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Intercellular Adhesion Molecule-1; Italy; Male; Middle Aged; Myocardial Infarction; Myocardium; Placebo Effect; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome; Vascular Cell Adhesion Molecule-1 | 2010 |
Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Triglycerides | 2010 |
More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome--sub-analysis of JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2010 |
Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: subgroup analysis of JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Adiponectin; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Logistic Models; Male; Middle Aged; Odds Ratio; Prospective Studies; Pyrroles; Quinolines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Triglycerides; Ultrasonography, Interventional; Up-Regulation | 2010 |
The effect of early and intensive statin therapy on ventricular premature beat or non-sustained ventricular tachycardia in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Chi-Square Distribution; China; Double-Blind Method; Drug Administration Schedule; Electrocardiography, Ambulatory; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Risk Assessment; Risk Factors; Tachycardia, Ventricular; Time Factors; Treatment Outcome; Ventricular Premature Complexes | 2010 |
On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
Topics: Acute Coronary Syndrome; Atorvastatin; C-Reactive Protein; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Risk Factors; Triglycerides | 2010 |
Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: the prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronar
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Combined Modality Therapy; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stents; Sulfonamides; Ticlopidine | 2010 |
Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
Topics: Acetates; Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Indoles; Keto Acids; Logistic Models; Male; Middle Aged; Phospholipases A2, Secretory; Prospective Studies; Pyrroles; Reference Values; Treatment Outcome | 2010 |
Higher baseline LDL-C levels amplify the short-term benefit of early intensive statin treatment in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, LDL; Cohort Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Pyrroles; Treatment Outcome | 2011 |
What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TI
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prognosis; Proportional Hazards Models; Pyrroles; Risk Factors; Thrombolytic Therapy; Treatment Outcome | 2010 |
Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Alanine Transaminase; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; C-Reactive Protein; Creatine Kinase, MB Form; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardium; Preoperative Care; Pyrroles; Treatment Outcome; Troponin I | 2010 |
[Atorvastatin in the treatment of high risk patients with ischemic heart disease and dyslipidemia. Safety assessment in the Russian Multicenter Study ATLANTIKA].
Topics: Acute Coronary Syndrome; Aged; Aspartate Aminotransferases; Atorvastatin; Comparative Effectiveness Research; Drug Dosage Calculations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Metabolic Networks and Pathways; Middle Aged; Monitoring, Physiologic; Pyrroles; Risk Assessment; Russia; Secondary Prevention; Treatment Outcome | 2010 |
Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; C-Reactive Protein; Chi-Square Distribution; China; Creatine Kinase, MB Form; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Secondary Prevention; Time Factors; Treatment Outcome; Troponin I | 2011 |
After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
Topics: Acetates; Acute Coronary Syndrome; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Keto Acids; Logistic Models; Male; Middle Aged; Phospholipases A2, Secretory; Pyrroles | 2011 |
The effect of early and intensive statin therapy on ventricular premature beat or nonsustained ventricular tachycardia in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Anti-Arrhythmia Agents; Atorvastatin; Chi-Square Distribution; China; Double-Blind Method; Drug Administration Schedule; Electrocardiography, Ambulatory; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Risk Assessment; Risk Factors; Tachycardia, Ventricular; Time Factors; Treatment Outcome; Ventricular Premature Complexes | 2011 |
Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Male; Middle Aged; Neopterin; Pravastatin; Proportional Hazards Models; Pyrroles; Sensitivity and Specificity; Treatment Outcome | 2011 |
Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Sex Characteristics; Stroke; Treatment Outcome | 2011 |
Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during an
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Coronary Angiography; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Kidney Function Tests; Male; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome | 2011 |
[Series: Clinical study from Japan and its reflections: introduction and summary of results: the ESTABLISH study].
Topics: Acute Coronary Syndrome; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Ultrasonography, Interventional | 2011 |
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR
Topics: Acute Coronary Syndrome; Adiponectin; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Recurrence; Risk Assessment | 2011 |
Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in ac
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Atherosclerosis; Atorvastatin; Chi-Square Distribution; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prospective Studies; Pyrroles; Quinolines; Regression Analysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome.
Topics: Acetates; Acute Coronary Syndrome; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Group II Phospholipases A2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-6; Keto Acids; Male; Middle Aged; Pyrroles; Treatment Outcome | 2011 |
Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial.
Topics: Acetates; Acute Coronary Syndrome; Atorvastatin; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Inflammation; Keto Acids; Phospholipases A2, Secretory; Pyrroles | 2012 |
[Association between high sensitivity C-reactive protein and contrast induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention: impact of atorvastatin].
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Contrast Media; Female; Heptanoic Acids; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pyrroles | 2011 |
Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).
Topics: Acute Coronary Syndrome; Adult; Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Survival Rate; Treatment Outcome; United States; Young Adult | 2012 |
Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Placenta Growth Factor; Pravastatin; Pregnancy Proteins; Pyrroles; Risk Factors | 2012 |
[Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study].
Topics: Acute Coronary Syndrome; Atorvastatin; Endosonography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrroles | 2011 |
[Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-aCS) study].
Topics: Acute Coronary Syndrome; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2011 |
Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: the JAPAN-ACS subanalysis study.
Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Atorvastatin; Biomarkers; Body Mass Index; Chi-Square Distribution; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Linear Models; Male; Metabolic Syndrome; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Quinolines; Time Factors; Treatment Outcome; Triglycerides; Ultrasonography, Interventional | 2012 |
Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy.
Topics: Acute Coronary Syndrome; Aged; Albuminuria; Anticholesteremic Agents; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pravastatin; Pyrroles; Risk Factors | 2013 |
[Relationship Between Lipid Lowering and Changes of Hemostasis and Inflammation During Use of Statins in Non-ST Elevation Acute Coronary Syndrome].
Topics: Acute Coronary Syndrome; Atorvastatin; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids | 2004 |
[The effects of 40 mg atorvastatin on serum lipids, inflammatory markers and clinical events in ACS patients post PCI].
Topics: Acute Coronary Syndrome; Alanine Transaminase; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Heptanoic Acids; Humans; Hypolipidemic Agents; Matrix Metalloproteinase 9; Prospective Studies; Pyrroles | 2006 |
Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Coronary Syndrome; Aged; Atorvastatin; Autoantibodies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin G; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 2008 |
Early effects of low versus high dose atorvastatin treatment on coagulation and inflammation parameters in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Atorvastatin; Blood Coagulation; C-Reactive Protein; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Pyrroles | 2008 |
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Pyrroles; Risk Factors; ROC Curve; Serum Amyloid A Protein; Stroke | 2008 |
Changes of CD4+CD25+ regulatory T cells in patients with acute coronary syndrome and the effects of atorvastatin.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Cytokines; Female; Flow Cytometry; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; T-Lymphocytes, Regulatory | 2007 |
[The antiplatelet effect of clopidogrel is not attenuated by statin treatment in patients with acute coronary syndromes undergone coronary stenting].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine | 2007 |
Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
Topics: Acute Coronary Syndrome; Aged; Anti-Infective Agents; Atorvastatin; Biomarkers; Calgranulin A; Calgranulin B; Case-Control Studies; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pravastatin; Probability; Pyrroles; Reference Values; Risk Assessment; Survival Rate; Thrombolytic Therapy; Treatment Outcome | 2008 |
Pregnancy-associated plasma protein-A elevation in patients with acute coronary syndrome and subsequent atorvastatin therapy.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pregnancy-Associated Plasma Protein-A; Pyrroles | 2008 |
Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents; Atorvastatin; Atrial Fibrillation; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Pravastatin; Pyrroles; Thrombolytic Therapy; Tirofiban; Tyrosine | 2008 |
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Triglycerides | 2008 |
High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) a
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Clopidogrel; Cytochrome P-450 Enzyme System; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Treatment Outcome | 2008 |
49 other study(ies) available for atorvastatin and Acute Coronary Syndrome
| Article | Year |
|---|---|
Effects of Statin Intensity on Long-term Outcomes After Coronary Artery Bypass Grafting.
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Bypass; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Percutaneous Coronary Intervention; Retrospective Studies; Treatment Outcome | 2022 |
New steps in acute coronary syndrome and antihyperlipidemic treatment: Determination of statins and metabolites by liquid chromatography tandem mass spectrometry.
Topics: Acute Coronary Syndrome; Atorvastatin; Chromatography, Liquid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Non-ST Elevated Myocardial Infarction; Rosuvastatin Calcium; ST Elevation Myocardial Infarction; Tandem Mass Spectrometry | 2022 |
Efficacy and Mechanism of Qianshan Huoxue Gao in Acute Coronary Syndrome via Regulation of Intestinal Flora and Metabolites.
Topics: Acute Coronary Syndrome; Animals; Atorvastatin; C-Reactive Protein; Ethanolamine; Ethanolamines; Gastrointestinal Microbiome; Interleukin-2; Interleukin-6; Male; Rats; Rats, Sprague-Dawley; RNA, Ribosomal, 16S; Tumor Necrosis Factor-alpha | 2023 |
Prescription of statins after acute coronary syndrome; a single-centre observational study.
Topics: Acute Coronary Syndrome; Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Percutaneous Coronary Intervention; Prescriptions; Treatment Outcome | 2023 |
Influencing Mechanism of Large-dose of Atorvastatin in Serum Visfatin, MMP-9, and Blood Fat Levels of Patients with Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Atorvastatin; C-Reactive Protein; Cholesterol; Humans; Matrix Metalloproteinase 9; Nicotinamide Phosphoribosyltransferase; Treatment Outcome | 2023 |
Statin versus ezetimibe-statin for incident atrial fibrillation among patients with type 2 diabetes mellitus with acute coronary syndrome and acute ischemic stroke.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Simvastatin; Stroke; Treatment Outcome | 2023 |
Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL-ACS Data.
Topics: Acute Coronary Syndrome; Atorvastatin; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Propensity Score; Rosuvastatin Calcium | 2023 |
Major Adverse Cardiovascular Events After 12 Months Among Patients With Acute Coronary Syndrome Receiving Loading Doses of Atorvastatin Prior to Planned PCI.
Topics: Acute Coronary Syndrome; Atorvastatin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Percutaneous Coronary Intervention | 2020 |
Association of in-hospital intensive statins dosage and death in arteriosclerotic cardiovascular disease with percutaneous coronary intervention: insights of multicentre cohort from China.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cause of Death; China; Cohort Studies; Female; Follow-Up Studies; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Postoperative Complications; Prognosis; Retrospective Studies; Risk Assessment | 2020 |
Secondary prevention after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Atorvastatin; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Percutaneous Coronary Intervention; Secondary Prevention | 2020 |
Clinical outcomes of high-intensity doses of atorvastatin in patients with acute coronary syndrome: A retrospective cohort study using real-world data.
Topics: Acute Coronary Syndrome; Aftercare; Atorvastatin; Humans; Male; Middle Aged; Patient Discharge; Retrospective Studies | 2021 |
Atorvastatin inhibits the immediate-early response gene EGR1 and improves the functional profile of CD4+T-lymphocytes in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Atorvastatin; Blotting, Western; CD4-Positive T-Lymphocytes; Cells, Cultured; Early Growth Response Protein 1; Female; Flow Cytometry; Gene Expression; Gene Expression Profiling; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocyte Activation; Male; Middle Aged; Polymerase Chain Reaction | 2017 |
Postoperative myocardial infarction in an orthognatic jaw surgery.
Topics: Acute Coronary Syndrome; Adult; Anesthesia, General; Angioplasty; Anticoagulants; Atorvastatin; Cardiovascular Agents; Combined Modality Therapy; Disease Susceptibility; Drug-Eluting Stents; Dyslipidemias; Early Diagnosis; Elective Surgical Procedures; Humans; Male; Maxilla; Orthognathic Surgery; Postoperative Complications; Smoking; Surgery, Plastic | 2017 |
The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational study.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Diabetes Mellitus; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Kidney Function Tests; Logistic Models; Male; Middle Aged; Percutaneous Coronary Intervention; Renal Insufficiency, Chronic; Simvastatin; Time Factors | 2017 |
Possible association of influenza A infection and reverse takotsubo syndrome.
Topics: Acute Coronary Syndrome; Aged; Antiviral Agents; Aspirin; Atorvastatin; Chest Pain; Coronary Angiography; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Influenza A virus; Influenza, Human; Oseltamivir; Platelet Aggregation Inhibitors; Takotsubo Cardiomyopathy; Treatment Outcome | 2018 |
Inclusion of multiple inappropriate studies in a meta-analysis of randomized controlled trials of atorvastatin loading prior to percutaneous coronary intervention for acute coronary syndrome: editor's response.
Topics: Acute Coronary Syndrome; Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic | 2019 |
Inappropriate inclusion of multiple studies in a meta-analysis of randomized controlled trials of atorvastatin loading prior to percutaneous coronary intervention for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic | 2019 |
Efficacy and Safety of Ezetimibe in Combination with Atorvastatin for Acute Coronary Syndrome Patients Accompanied with Type 2 Diabetes: A Single-Center, Non-randomized Cohort Study.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Lipids; Male; Middle Aged; Myocardium | 2019 |
[A multi-device approach to an unusual case of left main thrombosis: when manual thrombectomy is not enough].
Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Anticoagulants; Atorvastatin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Embolic Protection Devices; Embolism; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunoglobulin Fab Fragments; Infusions, Intra-Arterial; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Suction; Thrombectomy; Tomography, Optical Coherence | 2013 |
Impact of high-dose statin pre-treatment and contrast-induced acute kidney injury on follow-up events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Atorvastatin; Contrast Media; Disease-Free Survival; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Percutaneous Coronary Intervention; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Inflammation Activation Contributes to Adipokine Imbalance in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adipokines; Adiponectin; Animals; Atorvastatin; Blotting, Western; C-Reactive Protein; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mice; Mice, Inbred C57BL; Middle Aged; Myocardial Infarction; Resistin | 2016 |
Comparative Effectiveness of Generic Atorvastatin and Lipitor® in Patients Hospitalized with an Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Comparative Effectiveness Research; Drugs, Generic; Female; Hospitalization; Humans; Male; Propensity Score; Treatment Outcome | 2016 |
[JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome)].
Topics: Acute Coronary Syndrome; Atorvastatin; Evaluation Studies as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prospective Studies; Quinolines | 2016 |
Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.
Topics: Acute Coronary Syndrome; Aged; American Heart Association; Angina, Unstable; Atorvastatin; Cardiology; Cholesterol, LDL; Cohort Studies; Female; Guideline Adherence; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Practice Guidelines as Topic; Practice Patterns, Physicians'; Retrospective Studies; Rosuvastatin Calcium; Societies, Medical; Stroke; United States | 2016 |
Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Atorvastatin; Benzaldehydes; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Oximes; Phospholipase A2 Inhibitors; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Renal Insufficiency; Rosuvastatin Calcium; Secondary Prevention; Sex Factors; Simvastatin | 2017 |
Lipid management: considerations in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk Assessment; Risk Factors; Triglycerides | 2008 |
Effect of atorvastatin on hs-CRP in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2008 |
Epithelial neutrophil-activating peptide (ENA-78), acute coronary syndrome prognosis, and modulatory effect of statins.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Chemokine CXCL5; Cohort Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Male; Middle Aged; Neutrophils; Peptides; Prognosis; Prospective Studies; Pyrroles | 2008 |
Statin, the black box.
Topics: Acute Coronary Syndrome; Atorvastatin; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Effect of the TNFalpha-308 G/A polymorphism on the changes produced by atorvastatin in bone mineral density in patients with acute coronary syndrome.
Topics: Absorptiometry, Photon; Acute Coronary Syndrome; Amino Acids; Anticholesteremic Agents; Atorvastatin; Bone Density; Calcium; Cholesterol; Dose-Response Relationship, Drug; Female; Femur Neck; Follow-Up Studies; Genotype; Heptanoic Acids; Humans; Magnesium; Male; Middle Aged; Osteocalcin; Osteoporosis; Phosphorus; Polymerase Chain Reaction; Polymorphism, Genetic; Pyrroles; Risk Factors; Triglycerides; Tumor Necrosis Factor-alpha | 2008 |
Atorvastatin and BMD in coronary syndrome. Role of Lys656Asn polymorphism of leptin receptor gene.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Bone Density; Bone Remodeling; Female; Heptanoic Acids; Humans; Male; Middle Aged; Osteoporosis; Polymorphism, Genetic; Pyrroles; Receptors, Leptin | 2009 |
Seasonal variation in lipids: should we consider it more?
Topics: Acute Coronary Syndrome; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Seasons | 2009 |
Noninferiority of pitavastatin in intravascular ultrasound findings.
Topics: Acute Coronary Syndrome; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines; Reproducibility of Results; Treatment Outcome; Ultrasonography, Interventional | 2010 |
Statins in acute coronary syndromes and genetic insight.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Treatment Outcome | 2010 |
High-dose atorvastatin in acute coronary and cerebrovascular syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; Cerebrovascular Disorders; Coronary Circulation; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Outcome | 2010 |
[Managing myocardial infarct in general practice].
Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Anticoagulants; Atorvastatin; Blood Chemical Analysis; Chest Pain; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Education, Medical, Continuing; Electroencephalography; Family Practice; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Pyrroles; Risk Factors; Switzerland; Ticlopidine | 2010 |
Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cohort Studies; Dose-Response Relationship, Drug; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Multivariate Analysis; Primary Health Care; Proportional Hazards Models; Pyrroles; Risk Factors | 2011 |
Atorvastatin for reduction of myocardial damage during angioplasty trials.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents; Atorvastatin; Clopidogrel; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardium; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Treatment Outcome | 2010 |
Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Case-Control Studies; Female; Galectin 3; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Pravastatin; Prognosis; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Coronary Syndrome; Aged; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Lipoproteins; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; Oxidation-Reduction; Phospholipases A2, Secretory; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk; Risk Factors; Survival Analysis | 2012 |
Qualitative plaque stabilization but not quantitative plaque regression.
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2012 |
Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy--the extended JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Cerebral Infarction; Cholesterol, HDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Plaque, Atherosclerotic; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Quinolines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Highly upregulated expression of CD36 and MSR1 in circulating monocytes of patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Case-Control Studies; CD36 Antigens; Female; Gene Expression; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Middle Aged; Monocytes; Pyrroles; Real-Time Polymerase Chain Reaction; RNA, Messenger; Scavenger Receptors, Class A; Statistics, Nonparametric; Up-Regulation | 2012 |
Current statin usage for patients with acute coronary syndrome undergoing percutaneous coronary intervention: multicenter survey in Korea.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Chi-Square Distribution; Drug Utilization; Drug Utilization Review; Evidence-Based Medicine; Female; Fluorobenzenes; Guideline Adherence; Health Care Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prospective Studies; Pyrimidines; Pyrroles; Registries; Republic of Korea; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2012 |
Who benefits from statins? Patient or focal plaque?
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2012 |
Association between circulating matrix metalloproteinase levels and coronary plaque regression after acute coronary syndrome--subanalysis of the JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinases; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Quinolines; Remission Induction | 2013 |
[Results of ARMYDA-ACS trial show good outcome of 80 mg atorvastatin pretreatment in patients with acute coronary syndromes undergoing early percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Pyrroles; Treatment Outcome | 2007 |
Lipid levels in the post-acute coronary syndrome setting: destabilizing another myth?
Topics: Acute Coronary Syndrome; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Prognosis; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2008 |
Lipid levels after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heart Conduction System; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prognosis; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Time Factors; Triglycerides | 2008 |